Efficacy of Ciprofloxacin-Gentamicin Combination Therapy in Murine Bubonic Plague

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Lemaître, Nadine ^a,b,c,d,e   Ricard, Isabelle ^b,c,d,e   Pradel, Elizabeth ^b,c,d,e   Foligné, Benoît ^b,c,d,e   Courcol, René ^a,b,c,d,e   Simonet, Michel ^a,b,c,d,e   Sebbane, Florent ^b,c,d,e  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c INSERM U1019   (France)

^d Centre National de la Recherche Scientifique UMR8204   (France)

^e INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GENTAMICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BUBONIC PLAGUE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LIMIT OF DETECTION; LYMPH NODE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PLAGUE; SURVIVAL RATE; YERSINIA PESTIS; ZOONOSIS;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL LOAD; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FEMALE; GENTAMICINS; LYMPH NODES; MICE; MICROBIAL SENSITIVITY TESTS; PLAGUE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; YERSINIA PESTIS;

ANIMALIA; MURINAE; MUS; YERSINIA PESTIS;

EID: 84871454878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052503     Document Type: Article

References (30)

1. Butler T, (1994) Yersinia infections: centennial of the discovery of the plague bacillus. Clin Infect Dis 4: 655-661.
2. Bonacorsi SP, Scavizzi MR, Guiyoule A, Amouroux JH, Carniel E, (1994) Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection. Antimicrob Agents Chemother 38: 481-486.
3. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, et al. (2000) Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283: 2281-2290.
4. Russell P, Eley SM, Green M, Stagg AJ, Taylor RR, et al. (1998) Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J Antimicrob Chemother 41: 301-305.
5. World Health Organization (2008) Interregional meeting on prevention and control of plague. WHO/HSE/EPR/2008.3.
6. Heine HS, Louie A, Sorgel F, Bassett J, Miller L, et al. (2007) Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. J Infect Dis 196: 782-787.
7. Byrne WR, Welkos SL, Pitt ML, Davis KJ, Brueckner RP, et al. (1998) Antibiotic treatment of experimental pneumonic plague in mice. Antimicrob Agents Chemother 42: 675-681.
8. Lorange EA, Race BL, Sebbane F, Hinnebusch BJ, (2005) Poor vector competence of fleas and the evolution of hypervirulence in Yersinia pestis. J Infect Dis 191: 1907-1912.
9. Nham T, Filali S, Danne C, Derbise A, Carniel E, (2012) Imaging of bubonic plague dynamics by in vivo tracking of bioluminescent Yersinia pestis. PLoS One (7) (): e34714.
10. Sebbane F, Gardner D, Long D, Gowen BB, Hinnebusch BJ, (2005) Kinetics of disease progression and host response in a rat model of bubonic plague. Am J Pathol 166: 1427-1439.
11. Kumar A, Zarychanski R, Light B, Parillo J, Maki D, et al. (2010) Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 38: 1773-1785.
12. National Committee for Clinical and Laboratory Standards Institute (2006) Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically. Seventh Edition: Approved standards M7-A7. NCCLS, Wayne, PA, USA, 2006.
13. Odds FC, (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52: 1.
14. Pearson RD, Steigbigel RT, Davis HT, Chapman SW, (1980) Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother 18: 699-708.
15. Jolley ME, Stroupe SD, Wang CH, Panas HN, Keegan CL, et al. (1981) Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin Chem 27: 1190-1197.
16. Weber A, Chaffin D, Smith A, Opheim KE, (1985) Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother 27: 531-534.
17. Chalkley LJ, Koornhof HJ, (1985) Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother 28: 331-342.
18. Haller I, (1985) Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains. Antimicrob Agents Chemother 28: 663-666.
19. Mandal S, Mandal MD, Pal NK, (2003) Combination effect of ciprofloxacin and gentamicin against clinical isolates of Salmonella enterica serovar typhi with reduced susceptibility to ciprofloxacin. Jpn J Infect Dis 56: 156-157.
20. Zeiler HJ, Grohe K, (1984) The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol 3: 339-343.
21. Smith MD, Vinh DX, Nguyen TT, Wain J, Thung D, et al. (1995) In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Antimicrob Agents Chemother 39: 2153-2154.
22. Borner K, Höffken G, Lode H, Koeppe P, Prinzing C, et al. (1986) Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol 5: 179-186.
23. Demczar DJ, Nafziger AN, Bertino JS Jr, (1997) Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 41: 1115-1119.
24. Wang H, Cui Y, Wang Z, Wang X, Guo Z, et al. (2011) A dog-associated primary pneumonic plague in Qinghai Province, China. Clin Infect Dis 52: 185-190.
25. Bergan T, Engeset A, Olszewski W, Ostby N, Solberg R, (1986) Pharmacokinetics of ciprofloxacin in peripheral lymph and skin blisters. Eur J Clin Microbiol 5: 458-461.
26. Craig WA, (2011) Optimizing aminoglycoside use. Crit Care Clin 27: 107-121.
27. Easmon CS, Crane JP, (1985) Uptake of ciprofloxacin by macrophages. J Clin Pathol 38: 442-444.
28. Pujol C, Bliska JB, (2005) Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae. Clin Immunol 114: 216-226.
29. Reynolds AV, Hamilton-Miller JM, Brumfitt W, (1976) Diminished effect of gentamicin under anaerobic or hypercapnic conditions. Lancet 1: 447-449.
30. Kusser WC, Ishiguro EE, (1988) Effects of aminoglycosides and spectinomycin on the synthesis and release of lipopolysaccharide by Escherichia coli. Antimicrob Agents Chemother 32: 1247-1250.